Lisa H. Butterfield, PhD | Authors

Articles

Exploring the Efficacy of Pembrolizumab in Sarcoma Subtypes

August 31, 2017

Lisa H. Butterfield, PhD, professor of medicine, surgery, and immunology, director, University of Pittsburgh Immunologic Monitoring and Cellular Products Laboratory, and president of the Society for Immunotherapy of Cancer, discusses the SARC028 study, which explored the efficacy of pembrolizumab (Keytruda) in advanced soft tissue and bone sarcomas.

The Importance of Biomarkers for Cancer Immunotherapy

July 07, 2016

Immunotherapy for cancer has been studied in the laboratory and in early-phase trials for decades. Larger trials were not often successful enough, though in the last five years, a revolution has centered around the clinical success of checkpoint blockade with CTLA-4 and PD-1 antibodies.